Nucleophosmin-anaplastic Lymphoma Kinase (NPM-ALK), a Novel Hsp90-client Tyrosine Kinase: Down-regulation of NPM-ALK Expression and Tyrosine Phosphorylation in ALK(+) CD30(+) Lymphoma Cells by the Hsp90 Antagonist...
Overview
Affiliations
Anaplastic large cell lymphomas (ALCL) are characterized by the expression of a chimeric protein, NPM-ALK, which originates from fusion of the nucleophosmin (NPM) and the membrane receptor anaplastic lymphoma kinase (ALK) genes. The NPM-ALK kinase, on dimerization, shows phosphotransferase activity and, through its interaction with various ALK-adapter proteins, induces cell transformation and increases cell proliferation in vitro. The chaperones heat shock proteins 90 (Hsp90) and 70 (Hsp70) play a critical role in the folding and maturation of several oncogenic protein kinases, and perturbation of Hsp90 structure affects the stability and degradation of Hsp90- and Hsp70-bound substrates. This process is triggered by benzoquinone ansamycin antibiotics, Hsp90-binding small molecules. We have studied the effect of 17-allylamino,17-demethoxygeldanamycin (17-AAG), a benzoquinone ansamycin, on NPM-ALK steady-state level in ALCL cells. Treatment with 17-AAG decreased NPM-ALK expression and phosphorylation, thus impairing its association with phospholipase C-gamma, Src homology 2 domain-containing protein (Shc), growth factor receptor-bound protein 2 (Grb2), and insulin receptor substrate-1 (IRS-1). We also observed that NPM-ALK associates with Hsp90, and incubation with 17-AAG disrupts this complex without affecting Hsp90 expression. As shown previously for other Hsp90 client proteins, destabilization of the Hsp90/NPM-ALK complex induced by 17-AAG resulted in increased binding of the chimeric protein to Hsp70, which is known to affect protein degradation. Hsp/NPM-ALK complex formation appears to be independent of NPM sequences, because we were unable to coimmunoprecipitate NPM with either Hsp90 or Hsp70. Similar to NPM-ALK, the exogenously expressed variant fusion protein TPR-ALK showed decreased expression and phosphorylation after 17-AAG treatment, suggesting that the effect of 17-AAG on ALK chimeric proteins depends on the ALK portion and not on the partner protein moiety. Our data demonstrate that NPM-ALK cell content is determined by its interaction with Hsp90 and Hsp70, and suggest that the alteration of such associations can interfere with NPM-ALK function in ALCL cells.
Lovisa F, Garbin A, Crotti S, Di Battista P, Gallingani I, Damanti C Diagnostics (Basel). 2021; 11(2).
PMID: 33562105 PMC: 7915848. DOI: 10.3390/diagnostics11020253.
NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target.
Andraos E, Dignac J, Meggetto F Cancers (Basel). 2021; 13(1).
PMID: 33466277 PMC: 7795840. DOI: 10.3390/cancers13010144.
CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas.
Kuravi S, Parrott E, Mudduluru G, Cheng J, Ganguly S, Saunthararajah Y Blood Cancer J. 2019; 9(2):14.
PMID: 30696805 PMC: 6351628. DOI: 10.1038/s41408-019-0171-2.
Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives.
Cao Z, Gao Q, Fu M, Ni N, Pei Y, Ou W Oncol Lett. 2019; 17(2):2020-2030.
PMID: 30675269 PMC: 6341817. DOI: 10.3892/ol.2018.9856.
Jiang L, Xie C, Lung H, Lo K, Law G, Mak N Theranostics. 2018; 8(19):5307-5319.
PMID: 30555548 PMC: 6276081. DOI: 10.7150/thno.26823.